Bausch Health Companies Inc.
$22.14B- Market cap
- $2.41B
- Debt
- +$21.04B
- Cash
- −$1.31B
Capital structure 10% equity / 90% debt · EV / Revenue 2.16x · EV / EBITDA 9.15x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BHC stock price at discount vs HAYW $6.44 current versus $8.36 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at HAYW's multiple
Implied fair value · at BHC's multiple
Snapshot Sep 8, 2026, 2:53 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Value edge
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BHC FY 2025 (ended Dec 31, 2025) · HAYW FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 10% equity / 90% debt · EV / Revenue 2.16x · EV / EBITDA 9.15x
Capital structure 75% equity / 25% debt · EV / Revenue 3.12x · EV / EBITDA 11.45x
BHC carries the larger enterprise value at $22.14B against $3.50B; BHC trades on the lower EV / Revenue multiple (2.16x vs 3.12x); BHC on the lower EV / EBITDA (9.15x vs 11.45x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Bausch Health Companies Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Hayward Holdings, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-37.98x
0.60x
Net debt / EBITDA
Leverage against operating earnings
8.15x
1.84x
Cash and equivalents
Liquid reserves on the balance sheet
$1.31B
$399.11M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AbbVie Inc.
BHC vs ABBV
Organon & Co.
BHC vs OGN
TEVA PHARMACEUTICAL INDUSTRIES LTD
BHC vs TEVA
SUPERNUS PHARMACEUTICALS, INC.
BHC vs SUPN
ANI PHARMACEUTICALS INC
BHC vs ANIP
SMITH A O CORP
BHC vs AOS
LENNOX INTERNATIONAL INC
BHC vs LII
Johnson Controls International plc
BHC vs JCI
AAON, INC.
BHC vs AAON
Ingersoll Rand Inc.
BHC vs IR
Trane Technologies plc
BHC vs TT
$21.04B
$959.83M
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.